Clinical trial · Observational
Assessment of Remnant Liver Function in ALPPS by Gd-EOB-DTPA Enhanced MRI
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Insufficient future liver remnant (FLR), which may render post-hepatectomy liver failure, is one of the major obstacles for performing liver resection for patients with liver malignants. Associating liver partition and portal vein ligation (ALPPS) was introduced to induce rapid and extensive liver hypertrophy, which offers the opportunity for removing the liver malignancy in the second stage operation for patients with insufficient FLR at their first stage operation. Feasibility of the second stage of ALPPS has been assessed mostly on the basis of laboratory parameters and volumetry by the 3D reconstruction of CT. Meanwhile, part of the patients who underwent the second stage ALPPS still experienced postoperative liver failure, even in patients with sufficient FLR volume. In other words, this volumetric increase may not reflect the increase of liver function. And the laboratory parameters can only partly reflect the global liver function but not the regional liver function. Therefore, the combination of volumetric and global liver function tests might be unsuitable for predicting FLR function after first stage ALPPS because function is distributed unequally between left and right liver lobe. The Gd-EOB-DTPA-enhanced liver MRI, which has remarkable potential to evaluate regional liver function and could therefore be an ideal diagnostic test for performing volumetric and functional measurement after the first stage ALPPS in one examination. Thus we performed this clinical trial in order to evaluate the efficacy of Gd-EOB-DTPA-enhanced liver MRI in evaluating the FLR liver function after the first stage ALPPS.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Liver Function Failure | — | UNRESOLVED | — |
| Liver Malignant Tumors | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- Postoperative liver function failure
- timeFrame
- Within 90 days after the operation
- description
- The "50-50 criteria" was applied to assess post-treatment liver failure, which considers the increased total bilirubin level (\>50 umol/L) and decreased PTA (\<50%) on postoperative day 5.
Secondary outcomes (1)
- measure
- Postoperative morbidities and mortalities
- timeFrame
- Within 90 days after the operation
- description
- Postoperative morbidities and mortalities were graded according to the Clavien classification.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * future liver remnant volume \<30%; * indocyanine green clearance (ICG) rate \<20% at 15 minutes; * Child A liver function, serum platelet count \> 50×109/L; * good general condition. Exclusion Criteria: * complete right portal vein thrombosis; * serum platelet count \< 50×109/L; * clinical signs of portal hypertension such as ascites, and/or intra-abdominal varices.
References
Publications (0)
Data not yet available